Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2016 | Frontline therapy for multiple myeloma

Antonio Palumbo, MD, from the University of Turin, Turin, Italy provides advice on how to treat multiple myeloma (MM). For patients younger than 75, autologous transplantation remains the standard of care and Dr Palumbo also suggests a three-drug combination induction therapy. For patients who are not eligible for a transplant, the advice is also a three-drug combination, which includes proteasome inhibitors plus an alkylating agent or a proteasome inhibitor plus IMiDs. For frail patients who are not transplant eligible and also have co-morbidities, Dr Palumbo suggests a two-drug combination therapy.
Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.